Real‐world data for lenalidomide maintenance in responding patients of diffuse large B‐cell lymphoma
Abstract Background Approximately 40% patients of diffuse large B‐cell lymphoma (DLBCL) would develop disease recurrence/progression after first‐line R‐CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) induction therapy, with highly poor prognosis. An effective strategy to...
Zapisane w:
| Główni autorzy: | , , , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
Wiley
2023-05-01
|
| Seria: | Cancer Medicine |
| Hasła przedmiotowe: | |
| Dostęp online: | https://doi.org/10.1002/cam4.5790 |
| Etykiety: |
Nie ma etykietki, Dołącz pierwszą etykiete!
|